BIONXT SOLUTIONS INC (BXT.DE) Stock Price & Overview
FRA:BXT • CA0909741062
The current stock price of BXT.DE is 0.399 EUR. Today BXT.DE is up by 5%. In the past month the price increased by 2.31%. In the past year, price increased by 4.18%.
BXT.DE Key Statistics
- Market Cap
- 48.874M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.03
- Dividend Yield
- N/A
BXT.DE Stock Performance
BXT.DE Stock Chart
BXT.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BXT.DE. When comparing the yearly performance of all stocks, BXT.DE is a bad performer in the overall market: 76.05% of all stocks are doing better.
BXT.DE Earnings
On November 28, 2025 BXT.DE reported an EPS of -0.01 and a revenue of 13.97K.
BXT.DE Forecast & Estimates
BXT.DE Groups
Sector & Classification
BXT.DE Financial Highlights
Over the last trailing twelve months BXT.DE reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 10.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -503.75% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BXT.DE Ownership
BXT.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SNW | SANOFI | 8.94 | 184.528B | ||
| SAN | SANOFI | 8.94 | 184.503B | ||
| 1SAN | SANOFI | 8.96 | 184.165B | ||
| UCB | UCB SA | 24.93 | 48.822B | ||
| UNC | UCB SA | 24.23 | 48.764B | ||
| MRK | MERCK KGAA | 13.02 | 47.891B | ||
| 1MRK | MERCK KGAA | 12.53 | 47.869B | ||
| 1BAYN | BAYER AG-REG | 8.03 | 36.728B | ||
| BAYN | BAYER AG-REG | 8.03 | 35.75B | ||
| IPN | IPSEN | 12.64 | 13.485B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.39 | 9.8B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.614B | ||
| VIRP | VIRBAC SA | 15.97 | 2.907B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About BXT.DE
Company Profile
BioNxt Solutions, Inc. engages in the business of producing, extracting, and selling medical cannabis. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-08-06. The firm focuses on drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform. The targeted chemotherapy platform is designed to transform the way cytotoxic drugs are administered, by delivering active compounds directly into tumor tissue while minimizing exposure to healthy cells. Its product pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, and BNT24004. BNT23001 is a sublingual Cladribine film targeting multiple sclerosis (MS), offering improved bioavailability and patient convenience. BNT23002 is a sublingual Cladribine formulation for myasthenia gravis (MG), addressing the challenges of oral medication in patients with swallowing difficulties. BNT24002 is a sublingual thin film for the treatment of lupus nephritis (LN).
Company Info
IPO: 2019-08-06
BIONXT SOLUTIONS INC
Suite 270 - 1820 Fir Street
Vancouver BRITISH COLUMBIA CA
Employees: 0
Phone: 17808186422
BIONXT SOLUTIONS INC / BXT.DE FAQ
Can you describe the business of BIONXT SOLUTIONS INC?
BioNxt Solutions, Inc. engages in the business of producing, extracting, and selling medical cannabis. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-08-06. The firm focuses on drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform. The targeted chemotherapy platform is designed to transform the way cytotoxic drugs are administered, by delivering active compounds directly into tumor tissue while minimizing exposure to healthy cells. Its product pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, and BNT24004. BNT23001 is a sublingual Cladribine film targeting multiple sclerosis (MS), offering improved bioavailability and patient convenience. BNT23002 is a sublingual Cladribine formulation for myasthenia gravis (MG), addressing the challenges of oral medication in patients with swallowing difficulties. BNT24002 is a sublingual thin film for the treatment of lupus nephritis (LN).
What is the current price of BXT stock?
The current stock price of BXT.DE is 0.399 EUR. The price increased by 5% in the last trading session.
What is the dividend status of BIONXT SOLUTIONS INC?
BXT.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of BXT stock?
BXT.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists BXT stock?
BXT.DE stock is listed on the Frankfurt Stock Exchange exchange.
Should I buy BXT stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BXT.DE.
What is BIONXT SOLUTIONS INC worth?
BIONXT SOLUTIONS INC (BXT.DE) has a market capitalization of 48.87M EUR. This makes BXT.DE a Nano Cap stock.